Lekarze w zakresie Kolonoskopia za granicą — Strona 6

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. José Miguel Esteban López-Jamar is a gastroenterologist. He has led the Digestive Endoscopy and Digestive Diseases Units at Hospital Ruber Internacional since 2007. He has more than 20 years of experience. He is a Spanish pioneer in endoscopic ultrasound (EUS). His work covers diagnostic and interventional endoscopy. He uses innovative, minimally invasive techniques for complex gastrointestinal disease.

He was Head of Endoscopy (2008–2012) and Head of Endoscopic Innovation (2012–2014) at Hospital Clínico San Carlos. He completed international training at AMC Amsterdam, Institut Paoli-Calmettes in Marseille, and Zhongshan Hospital in Shanghai. He holds an MD and a PhD from the Complutense University of Madrid. He is a specialist in gastroenterology. He takes part in multicenter European studies and clinical trials. He is a member of SEPD, SEED, and ESGE.

Dr. Nihat Okcu is a gastroenterologist and gastrointestinal surgeon at Medipol University Pendik Hospital. He specializes in the treatment of complex digestive conditions and liver diseases. Dr. Okcu has published over 20 academic papers on gastric cancer and endoscopic diagnosis. He serves at a hospital with a 95.4% healthcare quality score.

• Performs laparoscopic anti-reflux surgery and small intestine resections.
• Expert in gastric polyps removal and duodenal polyp excision.
• Treats chronic conditions like cirrhosis, Crohn’s disease, and ulcerative colitis.
• Provides diagnostic gastroscopy with biopsy and ultrasound-guided procedures.

Dr. Mehmet Ali Gok is an Associate Professor of General Surgery at Medipol University Pendik Hospital. He specializes in laparoscopic hernia repair and metabolic surgery. Dr. Gok has authored over 20 national and international scientific articles on surgical outcomes. He practices at a hospital with 95.4 out of 96.4 healthcare quality points.

• Certified in robotic colorectal surgery and laparoscopic hernia techniques on cadavers.
• Received specialized training from the European Hernia Society in Dubai.
• Served as a former Chief Physician at Silopi State Hospital.
• Editor of several medical books on oncological, hernia, and minimal invasive surgery.

Dr. Nurana Guliyeva is a gastroenterologist at the Biological Medicine Integrative Health Center in Baku. She specializes in treating viral hepatitis, cirrhosis, and complex autoimmune liver diseases. Dr. Guliyeva completed an internship in microbiology and infectious diseases at Ege University in Turkey. She focuses on digestive health, including stomach, intestine, and pancreas disorders.

• Trained at Ege University and Hacettepe Hospital in Turkey.
• Treats viral hepatitis A, B, C, and D alongside drug-induced liver poisoning.
• Performs specialized procedures like colon hydrotherapy and gastric polyp removal.
• Works at an integrative health center treating over 84,000 patients annually.

Specjalizacje

Chirurgia nowotworowa

Chirurgia trzustki

Chirurgia dróg żółciowych

Chirurgia metaboliczna bariatryczna

Chirurgia Onkologiczna

Chirurgia piersi

Rak żołądka

Rak jelita grubego

Rak tarczycy

Chirurgia otyłości

Operacje cukrzycowe

Lekarz ukończył studia medyczne na Uniwersytecie Wiedeńskim w 1998 roku, odbywając szkolenie na UCLA i Uniwersytecie Pensylwanii. W latach 2000-2006 lekarz szkolił się jako specjalista w dziedzinie chorób wewnętrznych w Szpitalu Ogólnym w Wiedniu, a następnie dodatkowo specjalizował się w gastroenterologii i hepatologii w latach 2006-2008 oraz w intensywnej terapii wewnętrznej w latach 2008-2010.<\/p>

W 2003 roku lekarz założył i zarządzał laboratorium hemodynamiki wątrobowej oraz przychodnią dla pacjentów z marskością wątroby na Uniwersytecie Medycznym w Wiedniu. Od 2018 roku lekarz jest kierownikiem Oddziału Chorób Wewnętrznych I w Szpitalu Braci Miłosierdzia w Wiedniu.<\/p>

Lekarz jest specjalistą w zakresie chirurgii ogólnej i trzewnej, pracuje jako chirurg w Katedrze Chirurgii Ogólnej na Uniwersytecie Medycznym w Wiedniu. Kieruje zespołem chirurgii żołądka i przełyku, a także jest szefem jednostki nowotworów żołądkowo-przełykowych w Kompleksowym Centrum Onkologii w Wiedniu.<\/p>

Z ponad 240 opublikowanymi artykułami specjalistycznymi, lekarz pełnił znaczące role, takie jak Sekretarz Generalny Austriackiego Towarzystwa Chirurgii Onkologicznej od 2014 roku i Kierownik Usługi Górnego Przewodu Pokarmowego od 2012 roku. Lekarz jest profesorem nadzwyczajnym chirurgii i specjalistą w zakresie chirurgii górnego przewodu pokarmowego od 2007 roku.<\/p>

Lekarz ukończył Wydział Medycyny Uniwersytetu Stambulskiego Cerrahpasa i ma duże doświadczenie w zakresie medycyny wewnętrznej i gastroenterologii. Specjalistyczne szkolenie zostało ukończone w Szpitalu Szkoleniowo-Badawczym Haydarpaşa Numune, koncentrując się na gastroenterologii. Lekarz zajmował stanowiska w różnych szpitalach, w tym w Szpitalu Haydarpasha Nummune i Szpitalu Szkoleniowo-Badawczym Shishli Etfal, a także pracował w Prywatnej Poliklinice Unimed i Hospitallium Camlica.<\/p>

Specjalizacja obejmuje procedury takie jak ezofagogastroduodenoskopia, kolonoskopia, chromoendoskopia oraz różne leczenia krwawień i zwężeń przewodu pokarmowego. Lekarz jest biegły w zaawansowanych technikach, takich jak opaskowanie żylaków przełyku i przezskórna endoskopowa gastrostomia.<\/p>

Dr. Osman Aktas is a general surgeon at Avicenna International Hospital in Istanbul. He completed laparoscopic surgery training in Germany. He specializes in oncological and metabolic surgeries. Dr. Aktas previously served as chief physician at several prominent military hospitals.

• Performs complex cancer surgeries like the Whipple procedure and colorectal resections.
• Treats obesity and diabetes using metabolic surgery techniques.
• Manages gastrointestinal tumors and obstructions through minimally invasive methods.
• Uses laser therapy for modern treatment of anal diseases.

Lekarz ma 17-letnie doświadczenie w chirurgii górnego odcinka przewodu pokarmowego i operacjach odchudzających, będąc jednym z pierwszych w Indiach, którzy przeszli szkolenie w Los Angeles, USA, w zakresie metod Banded Bypass, Banded Sleeve Gastrectomy i Mini Gastric Bypass. Wykonuje innowacyjną Sleeve Gastrectomy z obejściem dwunastniczo-jelitowym, znaną ze swojej skuteczności w odchudzaniu i rozwiązywaniu problemu cukrzycy typu II, szczególnie dla pacjentów wegetariańskich. Przeszedł szkolenie we Włoszech w zakresie robotycznej chirurgii przewodu pokarmowego, wykorzystuje zaawansowane techniki dla precyzji i rekonwalescencji.<\/p>

Praktykuje chirurgię odchudzającą i metaboliczną z minimalnie inwazyjnymi technikami od 2009 roku, tylko 1% jego pacjentów doświadcza znacznej chorobowości, co jest zgodne z globalnymi standardami. Ponad 90% pacjentów z cukrzycą utrzymuje zdrowy styl życia bez insuliny lub leków doustnych.<\/p>

Lekarz zajmuje się skomplikowanymi przypadkami bariatrycznymi, w tym Sleeve Gastrectomy, Gastric Bypass i rewizyjną chirurgią bariatryczną. Jest biegły w zaawansowanych minimalnie inwazyjnych i robotycznych operacjach górnego odcinka przewodu pokarmowego i biliopankreatycznych, ma wiele publikacji i międzynarodowych wystąpień.<\/p>

Oddział chirurgii bariatrycznej jest certyfikowany jako centrum doskonałości przez Międzynarodową Fundację Doskonałości.<\/p>

Dr. Cheon Won Seok is the Director of the Department of Gastroenterology at Naeun Hospital. His expertise includes gastrointestinal diseases; upper gastrointestinal endoscopy and colonoscopy; polypectomy; ESD (Endoscopic Submucosal Dissection); small-bowel capsule endoscopy; digestive disorders; gastric and esophageal cancer; Helicobacter pylori infection; liver diseases; and inflammatory bowel disease, including Crohn’s disease and ulcerative colitis.

He graduated from Kyung Hee University College of Medicine. He completed his internship at Kyung Hee Medical Center and his internal medicine residency at Hallym University Sacred Heart Hospital. He later served as a Clinical Instructor in Gastroenterology at Chung-Ang University Hospital. He is a full member of the Korean Association of Internal Medicine and a life member of the Korean Society of Gastrointestinal Endoscopy. He is also a board-certified subspecialist in gastrointestinal endoscopy and serves as a medical advisor to KBS, MBC, SBS, JTBC, and MBN.

Dr. Holovyna Svitlana is a gastroenterologist and nutritionist with more than 23 years of experience. She is a member of the Association of Dietitians and Gastroenterologists of Ukraine. She also belongs to the European Association for the Study of the Liver (EASL) and the Association of Preventive and Anti-Age Medicine.

Dr. Holovyna diagnoses and treats gastrointestinal disorders, metabolic diseases, and nutrition-related issues. She uses an integrated and evidence-based approach. Her focus is on restoring digestive health, managing chronic conditions, and improving patient well-being with personalized diet and treatment plans.

Lekarz ukończył specjalizację z radioterapii onkologicznej na Wydziale Medycznym Uniwersytetu Marmara w latach 2012-2016. Wcześniej lekarz ukończył studia licencjackie z medycyny, prowadzone w języku angielskim, na tej samej uczelni w latach 2004-2011. Lekarz ma solidne podstawy w edukacji medycznej, zaczynając od szkoły średniej w Szkole Szesnastki w Şirvanie w Azerbejdżanie w latach 1998-2004.<\/p>

Dr. Turkan Ozturk Topcu is a clinical oncologist at Biruni University Hospital in Istanbul. She maintains professional ties with the MD Anderson Cancer Center in the USA. She specializes in the treatment of breast, lung, and gastrointestinal cancers. Dr. Topcu is a member of both ESMO and ASCO.

• Completed a fellowship at the Sunnybrook Odette Cancer Center Breast Clinic in Canada.
• Treats a wide range of conditions including liver, pancreatic, and gynecological cancers.
• Held clinical roles at major institutions like Moffitt Cancer Center in the USA.
• Works at Biruni University Hospital, a TEMOS-accredited facility in Turkey.

Dr. Abu Shamsiya Rami Nuamanovych is a surgical oncologist and gastrointestinal specialist at Dievo Surgery Center. He serves as a consultant for the World Health Organization regarding laparoscopic procedures. Dr. Nuamanovych has performed thousands of surgeries, including bariatric and complex cancer operations. He is the President of the Association of Arab Doctors of Ukraine.

• Expertise in laparoscopic hernia repair and gallbladder removal.
• Performs bariatric procedures like gastric bypass and sleeve gastrectomy.
• Treats gastrointestinal cancers, including stomach, colon, and rectal tumors.
• Member of the International Federation for the Surgery of Obesity (IFSO).

Dr. Meryem Keceli Basaran is an Associate Professor and pediatric gastroenterologist at Biruni University Hospital. She specializes in digestion, hepatology, and nutrition for children. Dr. Basaran is a member of ESPGHAN, the European authority on pediatric gastroenterology. She manages gastrointestinal food allergies and inflammatory conditions like Crohn’s disease. She works at a TEMOS-accredited university hospital in Istanbul.

• Specializes in care before and after liver transplantation.
• Treats irritable bowel syndrome, celiac disease, and ulcerative colitis.
• Expert in managing chronic diarrhea, malabsorption, and faecal incontinence.
• Performs specialized diagnostic colonoscopies and gastroscopies with biopsy.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)